
BiotechTV - News
With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline
15 min•26 februari 2025
Om avsnittet
CEO Richard Mason describes the company's philosophy, and covers programs such as a FGF21/GLP-1 that was recently licensed from a Chinese partner, an IL18, ZIP12, and more.
Fler avsnitt
Visa alla avsnitt av BiotechTV - NewsBiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.